Pasi KorhonenSummaryAffiliation: Orion Pharma Country: Finland Publications
| Collaborators
|
Detail Information
Publications
The Finnish Cancer Registry as follow-up source of a large trial cohort--accuracy and delayPasi Korhonen
Orion Pharma, Department of Biostatistics and Data Management, Espoo, Finland
Acta Oncol 41:381-8. 2002..8% were unknown to the Registry. The accuracy of the FCR data is high but the delay in case notification should be considered in epidemiological studies...
Effects of alpha-tocopherol and beta-carotene supplementation on gastric cancer incidence in male smokers (ATBC Study, Finland)Nea Malila
National Public Health Institute, Helsinki, Finland
Cancer Causes Control 13:617-23. 2002..This study investigated the effects of alpha-tocopherol and beta-carotene supplementation on the incidence of gastric cancer...
Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-upJarmo Virtamo
National Public Health Institute, Helsinki, Finland
JAMA 290:476-85. 2003..The preventive effects of alpha-tocopherol on prostate cancer require confirmation in other trials. Smokers should avoid beta-carotene supplementation...
Flavonol and flavone intake and the risk of intermittent claudication in male smokersTero Hirvonen
Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland
Eur J Epidemiol 19:305-11. 2004..63, 95% CI: 0.41-0.98). Adjustment for flavonol and flavone intake only marginally changed these associations. In conclusion, flavonol and flavone intake was not independently associated with the risk of intermittent claudication...
